Boston Scientific Corporation $BSX Shares Sold by BDF Gestion

Key Points

• BDF Gestion reduced its holdings in Boston Scientific Corporation by 9.8%, now owning 36,997 shares valued at approximately $3.97 million.
• Several institutional investors significantly increased their stakes in Boston Scientific during the first quarter, including GAMMA Investing LLC, which boosted its holdings by over 11,700%.
• Boston Scientific reported $5.06 billion in revenue for the last quarter, surpassing expectations, with a year-over-year revenue increase of 22.8%.

BDF Gestion lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 9.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,997 shares of the medical equipment provider's stock after selling 4,032 shares during the period. BDF Gestion's holdings in Boston Scientific were worth $3,974,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter worth about $27,000. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific during the 4th quarter worth about $25,000. Sunbeam Capital Management LLC acquired a new position in shares of Boston Scientific during the 4th quarter worth about $26,000. Finally, Ameriflex Group Inc. acquired a new position in Boston Scientific in the 4th quarter valued at approximately $31,000. Institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Leerink Partners started coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target on the stock. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Stock Down 0.4%

NYSE:BSX traded down $0.39 on Friday, hitting $97.84. The stock had a trading volume of 16,833,754 shares, compared to its average volume of 8,405,870. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market cap of $144.97 billion, a P/E ratio of 58.24, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The firm's fifty day simple moving average is $104.40 and its two-hundred day simple moving average is $102.10. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $0.62 EPS. The firm's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.